Cost Per Response of Certolizumab Pegol Versus Adalimumab Among Biologic-Naïve Patients With Moderate or Severe Rheumatoid Arthritis from the US Payer Perspective

Autor:	Y Sun, R Low, M Yassine, R Liu, P Ralston, A Chua, M Sénécal, J Stark, E Lee
Rok vydání:	2018
Předmět:	medicine.medical_specialty business.industry Health Policy Perspective (graphical) Public Health Environmental and Occupational Health medicine.disease Therapy naive Rheumatoid arthritis Internal medicine medicine Adalimumab Certolizumab pegol business medicine.drug
Zdroj:	Value in Health. 21:S194
ISSN:	1098-3015
DOI:	10.1016/j.jval.2018.04.1321
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cd5ee35ec17c1b618093743b1f9f71e6 https://doi.org/10.1016/j.jval.2018.04.1321 Zobrazit plný text záznamu Full Text from ScienceDirect